Modern biological/biotechnological medicinal products. Topical issues and prospects for development

The review provides with the information, related to the development, research and registration of new biological preparations, including the issues of terminology and classification. It also highlights the issues of and prospects for genetically engineered drugs, specific aspects of comparative studies to prove the similarity of a biosimilar and the original (reference) medicine, clinical use and interchangeability of preparations, prospects for the development of biotechnological medicines, expert evaluation of the quality of biological/ biotechnological medicines, modern methods of immunotherapy of allergic diseases by recombinant medicines, as well as the issues of cell technology and tissue engineering. The review also describes the topics discussed at the 14th International Conference «High Medical Technologies of 21st Century» (October 24-31, 2015, Spain), related to fundamental and applied research, development and introduction of new technologies and modern medicines into clinical practice.

биологические, биотехнологические препараты, орфанные препараты, препараты клеточной и тканевой терапии, специфическая иммунотерапия аллергических заболеваний, биоаналогичные (биоподобные) препараты, biological and biotechnological preparations, orphan drugs, preparations of cell and tissue therapy, specific immunotherapy of allergic diseases, biosimilars

1. Ignatiev PS, Tychinskiy VP, Vyshenskaya TV. The studying of lymphocyte activation by coherent phase microscopy. Almanah klinicheskoy meditsiny 2008; 17(2): 65–7 (in Russian).

2. Federal law «On circulation of medicines» ¹ 61-FZ, 22.12.2014 (in Russian).

3. Tsalman AYa, Vatazin AV, Vasilenko IA, Metelin VB, Vyshenskaya TV. The interference patterns of nuclear phase meter lymphocytes in kidney transplantation. Klinicheskaya nefrologiya 2010; (6): 43–7 (in Russian).

4. Directive 2001/83/EC of the European parliament and of the council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).

5. Vasilenko IA, Pashkin IN, Suslov VP, Vlasova EA. Dynamics of morphometric parameters of peripheral blood platelets as a criterion for assessing thrombogenicity dialysis membranes. Urologiya 2011; (2): 36–41 (in Russian).

6. Medunitsyn NV, Mironov AN, Movsesyants AA. Theory and practice of vaccinology. Moscow: Remedium; 2015 (in Russian).

7. Ushakov AYu, Feklisova LV, Meskin ER, Teder YuG, Volohovich TT, Pozhalostina LV. Clinical and laboratory efficacy of various Acipol schemes in treating children with acute enteric infections. Biopreparaty 2008; (2): 19–21 (in Russian)

8. Medunitsyn NV. Vaccinology. Moscow: Triada-X; 2010 (in Russian).

9. Tsybalova LM, Kiselev OI. Universal flu vaccine. Development, perspective of using. Voprosy virusologii 2012; 57(1): 9–14 (in Russian).

10. Medunitsyn NV, Pokrovskiy VI. Basics of vaccination and immunotherapy. Moscow: GEOTAR-Media; 2005 (in Russian).

11. Soldatov AA, Avdeeva ZhI, Alpatova NA, Medunitsyn NV, Lysikova SL. Orphan drugs, principles of registration and application. Biopreparaty 2015; 55(3): 4–16 (in Russian).

12. Nasonov EL, ed. Anti-B-cell therapy in rheumatology: Focus on rituximab. Moscow: IMA-PRESS; 2012 (in Russian).

13. Nasonov EL, Karateev AE, Klukvina NG. Pharmacotherapy. In: Nasonov EL, Nasonova VA, eds. Rheumatology: national guide. Moscow: GEOTAR-Media; 2008. P. 178–251 (in Russian).

14. Sigidin YaA, Lukina GV. Biological Therapy in Rheumatology. Moscow: Prakticheskaya meditsina; 2009 (in Russian).

15. Moiseenko VM. Features of monoclonal antibodies in the treatment of malignant tumors. Prakticheskaya onkologiya 2002; 3(4): 253–61 (in Russian).

16. Buch MH, Bingham SJ, Bejanaro V, Bryer D, White J, Reece R, et al. Therapy of patients with rheumatoid arthritis. Outcome of infliximab failures switched to etanercept. Arthr Care Res. 2007; 57: 448–53.

17. van Vollenhoven RF, Emery P, Bingham CO, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013; 72(9): 1496–502.

18. Gutheil J. The Promise of Monoclonal Antibodies for the Therapy of Cancer. Critical Rev Oncol Hematology 2001; 38: 1–2.

19. Avdeeva ZhI, Alpatova NÀ, Volkova RÀ, Lapteva LÊ. Medicinal Preparations based on monoclonal antibodies. Biopreparaty 2011; 42(2): 14–9 (in Russian).

20. Alpatova NA, Avdeeva ZhI, Soldatov AA, Medunitsyn NV, Bondarev VP, Mironov AN, Merkulov VA. Problems associated with the manifestation of the immunogenicity of the monoclonal antibody drugs in clinical use. Immunologiya 2014; (1): 28–32 (in Russian).

21. Guidelines on the quality, safety, and efficacy of biotherapeutic protein products prepared by recombinant DNA technology. Replacement of Annex 3 of WHO Technical Report Series, ¹ 814 World Health Organization October 2013.

22. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself. 2010; (1): 314–22.

23. ICH S6(R1) guideline. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Geneva, International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2011.

24. Guideline on similar biological medicinal products (CHMP/437/04 Rev 1).

25. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CHMP/BMWP/42832/2005 Rev 1).

26. Guidance for Industry. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. U. S. Department of Health and Human Services Food and Drug Administration. Biosimilarity. February. 2012.

27. Guidance on the expertise of drugs. V. I. Moscow: Grif i K; 2013 (in Russian).

28. Niederwieser D, Schmitz S. Biosimilar agents in oncology?haematology: from approval to Practice. Eur J Haemat. 2011; 86: 277–88.

29. Vasilenko IA. Interchangeability of drugs: comparative aspects. Razrabotka i registratsiya lekarstvennyh sredstv 2014; 1(6): 146–52 (in Russian).

30. Soldatov AA, Avdeeva ZhI, Medunitsyn NV. Mechanisms for immediate type allergic reactions, preparations and methods of specific immunotherapy. Immunologiya 2016; 37(1): 52–61 (in Russian).

31. Guschin IS. IgE-mediated hypersensitivity in response to the violation of the barrier function of the tissue. Immunologiya 2015; 36(1): 45–52 (in Russian).

32. Soldatov AA, Medunitsyn NV, Avdeeva ZhI, Bondarev VP, Mironov AN. Therapeutic allergens: problems and ways to improve quality, safety and efficacy. Vedomosti Nauchnogo tsentra ekspertizy sredstv meditsinskogo primeneniya 2013; (4): 31–8 (in Russian).

33. Thomas WR, Hales BJ, Smith WA. House dust mite allergens in asthma and allergy. Trends Mol Med 2010; (16): 321–8.

34. Purohit A, Niederberger V, Kronqvist M, Horak F, Grunneberg R, Suck R, et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008; 38(9): 1514–25.

35. Moldaver D, Larche M. Immunotherapy with peptides. Allergy 2011; 66(6): 784–91.

36. Edlmayr J, Niespodziana K, Focke-Tejkl M, Linhart B, Valenta R. Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases. Curr Top Microbiol Immunol. 2011; (352): 121–40.

37. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens. J Allergy Clin Immunol. 2014; (133): 621–31.

38. Stella JA, D’Amore A, Wagner WR, Sacks MS. On the biomechanical function of scaffolds for engineering load-bearing soft tissues. Acta Biomater. 2010; 6(7): 2365–81.

39. Chen G, Ushida T, Tateish T. Scaffold design for tissue engineering. Macromol Biosci. 2002; (2): 67–77.

40. Kuznetsova DS, Timashev PS, Bagratashvili VI, Zagaynova EV. Bone implants based scaffolds and cell systems in tissue engineering (review). Sovremennye tehnologii v meditsine 2014; 6(4): 201–12 (in Russian).

41. Plosker GL, Keam SJ. Omalizumab: a review of its use in the treatment of allergic asthma. BioDrugs 2008; (22): 189–204.

42. Kolokoltseva TD, Saburina IN, Kubatiev AA. The culture of human and animal cells: isolation, culturing, cryopreservation and control. Patogenez 2015; 13(2): 50–65 (in Russian).

43. Kosheleva NV, Zurina IM, Saburina IN, Gorkun AA, Kolokoltseva TD, Borzenok SA, Repin VS. Influence of fetal calf serum on the formation of spheroids limb eyes stromal cells. Patogenez 2015; 13(2): 4–11 (in Russian).

44. Makarov MS, Storozheva MV, Konyushko OI, Borovkova NV, Hvatov VB. Effect of platelet derived growth factor concentration on the proliferative activity of human fibroblasts. Kletochnye tehnologii v biologii i meditsine 2013; (2): 111–5 (in Russian).

45. Ignatiev PS, Tychinskiy VP, Vyshenskaya TV. The studying of lymphocyte activation by coherent phase microscopy. Almanah klinicheskoy meditsiny 2008; 17(2): 65–7 (in Russian).

46. Tsalman AYa, Vatazin AV, Vasilenko IA, Metelin VB, Vyshenskaya TV. The interference patterns of nuclear phase meter lymphocytes in kidney transplantation. Klinicheskaya nefrologiya 2010; (6): 43–7 (in Russian).

47. Vasilenko IA, Pashkin IN, Suslov VP, Vlasova EA. Dynamics of morphometric parameters of peripheral blood platelets as a criterion for assessing thrombogenicity dialysis membranes. Urologiya 2011; (2): 36–41 (in Russian).

48. Ushakov AYu, Feklisova LV, Meskin ER, Teder YuG, Volohovich TT, Pozhalostina LV. Clinical and laboratory efficacy of various Acipol schemes in treating children with acute enteric infections. Biopreparaty 2008; (2): 19–21 (in Russian)